This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication

trusted source


Novel positron emission tomography tracer visualizes synucleinopathies

Novel positron emission tomography tracer to visualize synucleinopathies
The discovery of F0502B represents a promising lead compound for imaging α-synuclein inclusions in synucleinopathies. Credit: Ye Keqiang

Brain imaging scans are powerful tools for diagnosing Parkinson's disease (PD) and ruling out other motor disorders. In PD, the presence of α-synuclein (α-Syn) in Lewy bodies and Lewy neurites in the brain, particularly the substantia nigra, distinguishes it from other parkinsonisms. Unfortunately, there is currently no effective α-Syn PET tracer available.

Now, a research team led by Prof. Ye Keqiang from the Shenzhen Institute of Advanced Technology (SIAT) of the Chinese Academy of Sciences has discovered a promising compound called F0502B for imaging α-Syn and aiding in the diagnosis of synucleinopathies. The study was published in Cell on July 7.

The researchers found that in monkey PD models, [18F]-labeled F0502B specifically bound to α-Syn fibrils with high affinity, distinguishing them from Aβ and Tau fibrils.

PET imaging in monkey models showed that [18F]-F0502B specifically detected α-Syn aggregates. The levels of aggregated α-Syn may increase over time, leading to elevated PET-specific binding signals.

F0502B can act as neuroimaging radiotracer due to its certain chemical and pharmacological properties, including high permeability through the , rapid clearance from normal tissue and blood, and high-affinity binding and selectivity for the target.

"Our findings demonstrate that F0502B acts as a specific PET tracer by selectively binding to aggregated α-Syn," said Prof. Ye, corresponding author of the study. "This could enhance our understanding of disease progression and potentially facilitate monitoring therapeutic efficacy in clinical trials."

More information: Jie Xiang et al, Development of an α-synuclein positron emission tomography tracer for imaging synucleinopathies, Cell (2023). DOI: 10.1016/j.cell.2023.06.004

Journal information: Cell
Citation: Novel positron emission tomography tracer visualizes synucleinopathies (2023, July 10) retrieved 23 May 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Translational PET tracer visualizes brain cholesterol metabolism


Feedback to editors